260418-25-5

Upstream product

• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 145325-42-4 1',5'-bis<2-methoxy-(4-methoxycarbonyl)phenoxy>pentane 
• 145325-48-0 1',5'-bis(4-carboxy-2-methoxy-5-nitrophenoxy)pentane 
• 145325-45-7 1',5'-bis[2-methoxy-4-(methoxycarbonyl)-5-nitrophenoxy]pentane 
• 260417-93-4 benzyl (2S,4R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-4-hydroxypyrrolidine-1-carboxylate 
• 260417-94-5 (2S,4R)-2-tert-butyldimethylsilyloxymethyl-4-hydroxypyrrolidine 
• 913262-30-3 1,1'-[[(pentane-1,5-diyl)dioxy]bis[(2S,4R)-(5-methoxy-2-nitro-1,4-phenylene)carbonyl]]bis[2-(tert-butyldimethylsilyloxymethyl)-4-hydroxyacetylpyrrolidine] 
• 13504-85-3 (2S,4R)-1-(benzyloxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid 
• 95687-41-5 (2S,4R)-N1-(benzyloxycarbonyl)-4-hydroxy-2-(hydroxymethyl)-pyrrolidine 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 64187-48-0 methyl (2S,4R)-1-benzyloxycarbonyl-4-hydroxypyrrolidine-2-carboxylate 
• 111-29-5 1 ,5-pentanediol 

Downstream Products

• 1343407-55-5 (5S,5’S)-1,1‘-(4,4‘-(pentane-1,5-diylbis(oxy))bis(5-methoxy-2-nitrobenzoyl))bis(5-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-3-one) 
• 1343407-56-6 (5S,5’S)-1,1‘-(4,4‘-(pentane-1,5-diylbis(oxy))bis(5-methoxy-2-nitrobenzoyl))bis(5-(((tert-butyldimethylsilyl)oxy)methyl)-4,5-dihydro-1H-pyrrole-3,1-diyl) bis(trifluoromethanesulfonate) 
• 260418-29-9 1,1'-[[(pentane-1,5-diyl)dioxy]-bis[(2-amino-N-allyloxycarbonyl-5-methoxy-1,4-phenylene)carbonyl]]-bis[(2S)-2-t-butyldimethylsilyloxymethyl-4-methylidene-2,3-dihydropyrrole] 
• 260418-27-7 1,1'-[[(pentane-1,5-diyl)dioxy]-bis[(2-amino-N-allyloxycarbonyl-5-methoxy-1,4-phenylene)carbonyl]]-bis[(2S,4R)-2-t-butyldimethylsilyloxymethyl-4-hydroxypyrrolidine] 
• 260418-28-8 1,1'-[[(pentane-1,5-diyl)dioxy]-bis[(2-amino-N-allyloxycarbonyl-5-methoxy-1,4-phenylene)carbonyl]]-bis[(2S)-2-t-butyldimethylsilyloxymethyl-4-oxo-pyrrolidine] 
• 260418-30-2 1,1'-[[(pentane-1,5-diyl)dioxy]-bis[(2-amino-N-allyloxycarbonyl-5-methoxy-1,4-phenylene)carbonyl]]-bis[(2S)-2-hydroxymethyl-4-methylidene-2,3-dihydropyrrole] 
• 260418-26-6 1,1'-[[(pentane-1,5-diyl)dioxy]-bis[(2-amino-5-methoxy-1,4-phenylene)carbonyl]]-bis[(2S,4R)-2-t-butyldimethylsilyloxymethyl-4-hydroxypyrrolidine] 

Relevant academic research and scientific papers

SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES

Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody that binds CD19 and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzod

SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES

Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody, which binds CD25 and comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiaze

SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES

Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antiobody moiety, all

SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES

Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody, which binds HER2 and comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiaze

SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES

Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antiobody moiety, all

SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES

Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody which binds PSMA, and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine and pyrrolobenzo

SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES

Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody, which binds MUC1 and comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiaze

ANTIBODIES AND ANTIBODY-DRUG CONJUGATES

This application provides antibodies and antigen binding fragments thereof which are capable of specifically binding the 5T4 cell surface antigen, antibody-drug conjugates, and antibody-imaging agent conjugates, as well as means and methods for producing and using them.

PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF

RJW/FP7067259 150 ABSTRACT A compound which is selected from A: A O OO O O O I O NH O O O O O O O O N H N H N H OO OH H O N N OO H N N B: 5 B O OO O O O Br O NH O O O O O O O O N H N H N H OO OH H O N N OO H N N; and C C O O N H N H O N H OO OO O O N O OO

HUMANIZED ANTI-TN-MUC1 ANTIBODIES AND THEIR CONJUGATES

Humanized anti-Tn-MUC1 antibodies and conjugates thereof. Conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to the antibody are described.